CYP2C19 and breast cancer: A total of 16 patients with trastuzumab-resistant breast cancer were tested using NGS in our hospital, in these patients, the frequency of genetic changes was ranked as the top four in the order of TP53, PIK3CA, CDK12 and CYP2C19 (Fig. 4C).